|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sonoda Y: Management of early ovarian
cancer. Oncology (Williston Park). 18:343–362. 2004.
|
|
3
|
Katsumata N, Yasuda M, Isonishi S,
Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S,
Terauchi F, et al Japanese Gynecologic Oncology Group: Long-term
results of dose-dense paclitaxel and carboplatin versus
conventional paclitaxel and carboplatin for treatment of advanced
epithelial ovarian, fallopian tube, or primary peritoneal cancer
(JGOG 3016): A randomised, controlled, open-label trial. Lancet
Oncol. 14:1020–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coward JI, Middleton K and Murphy F: New
perspectives on targeted therapy in ovarian cancer. Int J Womens
Health. 7:189–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Teplinsky E and Muggia F: Targeting HER2
in ovarian and uterine cancers: Challenges and future directions.
Gynecol Oncol. 135:364–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bamberger ES and Perrett CW: Angiogenesis
in epithelian ovarian cancer. Mol Pathol. 55:348–359. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Longo R, Sarmiento R, Fanelli M,
Capaccetti B, Gattuso D and Gasparini G: Anti-angiogenic therapy:
Rationale, challenges and clinical studies. Angiogenesis.
5:237–256. 2002. View Article : Google Scholar
|
|
9
|
Cannistra SA, Matulonis UA, Penson RT,
Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D,
Wenham R, et al: Phase II study of bevacizumab in patients with
platinum-resistant ovarian cancer or peritoneal serous cancer. J
Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garcia AA, Hirte H, Fleming G, Yang D,
Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D,
et al: Phase II clinical trial of bevacizumab and low-dose
metronomic oral cyclophosphamide in recurrent ovarian cancer: A
trial of the California, Chicago, and Princess Margaret Hospital
phase II consortia. J Clin Oncol. 26:76–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spannuth WA, Sood AK and Coleman RL:
Angiogenesis as a strategic target for ovarian cancer therapy. Nat
Clin Pract Oncol. 5:194–204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garrett KP, Aso T, Bradsher JN, Foundling
SI, Lane WS, Conaway RC and Conaway JW: Positive regulation of
general transcription factor SIII by a tailed ubiquitin homolog.
Proc Natl Acad Sci USA. 92:7172–7176. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stebbins CE, Kaelin WG Jr and Pavletich
NP: Structure of the VHL-ElonginC-ElonginB complex: Implications
for VHL tumor suppressor function. Science. 284:455–461. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou J, Wu K, Gao D, Zhu G, Wu D, Wang X,
Chen Y, Du Y, Song W, Ma Z, et al: Reciprocal regulation of
hypoxia-inducible factor 2α and GLI1 expression associated with the
radiore-sistance of renal cell carcinoma. Int J Radiat Oncol Biol
Phys. 90:942–951. 2014. View Article : Google Scholar
|
|
15
|
Cascone T, Herynk MH, Xu L, Du Z, Kadara
H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, et al:
Upregulated stromal EGFR and vascular remodeling in mouse xenograft
models of angiogenesis inhibitor-resistant human lung
adenocarcinoma. J Clin Invest. 121:1313–1328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grepin R, Guyot M, Jacquin M, Durivault J,
Chamorey E, Sudaka A, Serdjebi C, Lacarelle B, Scoazec JY, Negrier
S, et al: Acceleration of clear cell renal cell carcinoma growth in
mice following bevacizumab/Avastin treatment: The role of CXCL
cytokines. Oncogene. 31:1683–1694. 2012. View Article : Google Scholar
|
|
18
|
Huang D, Ding Y, Zhou M, Rini BI, Petillo
D, Qian CN, Kahnoski R, Futreal PA, Furge KA and Teh BT:
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib
in renal cell carcinoma. Cancer Res. 70:1063–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abraham RT: Chemokine to the rescue:
Interleukin-8 mediates resistance to PI3K-pathway-targeted therapy
in breast cancer. Cancer Cell. 22:703–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al:
Phase II trial of single-agent bevacizumab followed by bevacizumab
plus irinotecan at tumor progression in recurrent glioblastoma. J
Clin Oncol. 27:740–745. 2009. View Article : Google Scholar :
|
|
21
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Escudier B, Bellmunt J, Négrier S, Bajetta
E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S and
Sneller V: Phase III trial of bevacizumab plus interferon alfa-2a
in patients with metastatic renal cell carcinoma (AVOREN): Final
analysis of overall survival. J Clin Oncol. 28:2144–2150. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al Gynecologic Oncology Group: Incorporation of bevacizumab in
the primary treatment of ovarian cancer. N Engl J Med.
365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al ICON7 Investigators: A phase 3 trial
of bevacizumab in ovarian cancer. N Engl J Med. 365:2484–2496.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: The AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Escudier B, Pluzanska A, Koralewski P,
Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar
B, Bajetta E, et al AVOREN Trial investigators: Bevacizumab plus
interferon alfa-2a for treatment of metastatic renal cell
carcinoma: A randomised, double-blind phase III trial. Lancet.
370:2103–2111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shojaei F, Lee JH, Simmons BH, Wong A,
Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD and
Christensen JG: HGF/c-Met acts as an alternative angiogenic pathway
in sunitinib-resistant tumors. Cancer Res. 70:10090–10100. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Figlin RA, Kaufmann I and Brechbiel J:
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New
strategies for overcoming resistance to VEGFR and mTORC1
inhibitors. Int J Cancer. 133:788–796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Metallo CM, Gameiro PA, Bell EL, Mattaini
KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L,
et al: Reductive glutamine metabolism by IDH1 mediates lipogenesis
under hypoxia. Nature. 481:380–384. 2012.
|
|
31
|
Smerdel MP, Steffensen KD, Waldstrøm M,
Brandslund I and Jakobsen A: The predictive value of serum VEGF in
multi-resistant ovarian cancer patients treated with bevacizumab.
Gynecol Oncol. 118:167–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haase VH: The VHL tumor suppressor: Master
regulator of HIF. Curr Pharm Des. 15:3895–3903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Horwitz E, Stein I, Andreozzi M, Nemeth J,
Shoham A, Pappo O, Schweitzer N, Tornillo L, Kanarek N, Quagliata
L, et al: Human and mouse VEGFA-amplified hepatocellular carcinomas
are highly sensitive to sorafenib treatment. Cancer Discov.
4:730–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
